Centene Corporation
NYSE:CNCMedical - Healthcare Plans
+$0.67 today
- Market cap
- $33.39B
- Beta
- 1.09
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$13.09
Volume 6.29M
Average 6.16M
CNC Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Centene CorporationNYSE: CNC
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue dips below year-ago levels
Q2 FY2026 cost of revenue of $39.76B fell 13.2% year over year, behind the +0.1% change in trailing-twelve-month cost of revenue. Sequentially, it rose 1.9% from the prior quarter. Over 3 fiscal years it compounded at +10.2% a year.
Context
- Cost of revenue amounted to 87.8% of revenue in FY2025, down 1.9 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -13.2% toward the trailing-twelve-month pace of +0.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 170.94B USD
- Year-over-year change
- +16.9%
- 4-year CAGR
- +11.2%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 170.94B | +16.9% |
| FY2024 | 2024-12-31 | 146.24B | +7.0% |
| FY2023 | 2023-12-31 | 136.68B | +6.9% |
| FY2022 | 2022-12-31 | 127.89B | +14.4% |
| FY2021 | 2021-12-31 | 111.78B | — |
Cost of Revenue vs competitors
How CNC compares with its peers on the latest reported figures
- CNC's LTM Jun 2026 cost of revenue of $162.49B is the 4th highest of the 9 companies compared; the peer median is $131.09B.
- Its year-over-year change of +0.1% is the 6th highest of 9, against a peer median of +6.7%.
- Cost of revenue amounts to 83.9% of revenue for CNC, versus a peer median of 86.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $356.34B | +6.9% | +9.0% | 85.8% | |
| LTM Sep 2026 | $347.08B | -0.7% | +14.2% | 77.2% | |
| LTM Sep 2026 | $256.93B | +6.5% | +16.6% | 89.7% | |
| LTM Jun 2026 | $162.49B | +0.1% | +10.2% | 83.9% | |
| LTM Sep 2026 | $134.12B | +24.8% | +13.5% | 87.0% | |
| LTM Sep 2026 | $128.05B | -10.9% | +8.3% | 63.4% | |
| LTM Sep 2026 | $40.11B | +0.1% | +13.8% | 91.9% | |
| LTM Jun 2026 | $8.44B | +22.7% | — | 55.1% | |
| LTM Mar 2026 | $3.73B | +40.5% | +40.4% | 87.6% | |
| Peer median (excluding CNC) | $131.09B | +6.7% | +13.8% | 86.4% | |
Competitors are the stored peer set for CNC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 125.98B | 144.55B | 154B | 163.07B | 194.78B |
| Cost of Revenue | 111.78B | 127.89B | 136.68B | 146.24B | 170.94B |
| Gross Profit | 14.2B | 16.66B | 17.32B | 16.83B | 23.83B |
| Gross Margin | 11.3% | 11.5% | 11.2% | 10.3% | 12.2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 9.6B | 11.59B | 12.56B | 12.4B | 13.26B |
| Operating Expenses | 12.42B | 15.34B | 14.39B | 13.65B | 31.45B |
| Depreciation & Amortization | 1.48B | 1.55B | 1.29B | 1.24B | 1.28B |
| EBITDA | 3.95B | 4.18B | 5.62B | 6.2B | (5.14B) |
| EBITDA Margin | 3.1% | 2.9% | 3.6% | 3.8% | -2.6% |
| Operating Income | 1.78B | 1.32B | 2.93B | 3.18B | (7.62B) |
| Operating Margin | 1.4% | 0.9% | 1.9% | 1.9% | -3.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 665M | 665M | 725M | 702M | 678M |
| Other Income / Expenses | 29M | 644M | 668M | 1.08B | 890.41M |
| Income Before Tax | 1.81B | 1.96B | 3.6B | 4.26B | (6.73B) |
| Pre-Tax Margin | 1.4% | 1.4% | 2.3% | 2.6% | -3.5% |
| Income Tax Expense | 477M | 760M | 899M | 963M | (50.96M) |
| Net Income | 1.35B | 1.2B | 2.7B | 3.31B | (6.67B) |
| Net Margin | 1.1% | 0.8% | 1.8% | 2.0% | -3.4% |
| EPS (Basic) | 2.31 | 2.09 | 4.97 | 6.33 | (13.61) |
| EPS (Diluted) | 2.28 | 2.07 | 4.95 | 6.31 | (13.62) |
| Weighted Avg Shares | 582.83M | 575.19M | 543.32M | 521.79M | 491.07M |
| Weighted Avg Shares (Diluted) | 590.52M | 582.04M | 545.7M | 523.74M | 491.07M |
Centene Corporation
NYSE:CNC
Intrinsic Alpha fair value
Locked
Current Price
$67.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.